Compare
Guided Therapeutics Inc vs iTonic Holdings Ltd vs Neuraxis, Inc vs Nuwellis, Inc.
| Latest fiscal year | Guided Therapeutics Inc GTHP | iTonic Holdings Ltd ITOC | Neuraxis, Inc NRXS | Nuwellis, Inc. NUWE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $767.0K | $523.0K | $3.57M | $8.27M |
| Revenue growth (YoY) | n/m | +16.7% | +32.9% | -5.4% |
| Gross margin | 74.4% | 62.6% | 84.2% | 62.0% |
| Operating margin | -309.3% | -991.7% | -219.4% | -134.3% |
| Net margin | -416.7% | -974.7% | -218.5% | -211.9% |
| Net income | -$3.20M | -$5.10M | -$7.80M | -$17.52M |
| EPS (Diluted) | -$0.04 | -$0.32 | -$0.95 | -$25.39 |
| Operating cash flow | -$1.07M | -$3.23M | -$6.43M | -$10.81M |
| Free cash flow | -$1.07M | -$3.24M | -$6.46M | -$10.90M |
| Cash & equivalents | n/a | $1.49M | $4.97M | $1.08M |
| Total assets | $1.32M | $9.10M | $6.40M | $6.12M |
| Total liabilities | $7.33M | $969.8K | $3.00M | $3.49M |
| Shareholders' equity | -$6.01M | $6.12M | $3.40M | $2.62M |
| Return on year-end equity | n/a | -83.3% | -229.5% | -667.7% |
| Shares outstanding | 86.15M | n/a | 10.65M | 1.69M |
Revenue, most recent five fiscal years
| Fiscal year | Guided Therapeutics Inc | iTonic Holdings Ltd | Neuraxis, Inc | Nuwellis, Inc. |
|---|---|---|---|---|
| Latest | $767.0K Ended 2025-12-31 | $523.0K Ended 2025-12-31 | $3.57M Ended 2025-12-31 | $8.27M Ended 2025-12-31 |
| 1 year earlier | $7.0K Ended 2024-12-31 | $448.2K Ended 2024-12-31 | $2.69M Ended 2024-12-31 | $8.74M Ended 2024-12-31 |
| 2 years earlier | $98.0K Ended 2023-12-31 | $628.6K Ended 2023-12-31 | $2.46M Ended 2023-12-31 | $8.86M Ended 2023-12-31 |
| 3 years earlier | $13.0K Ended 2022-12-31 | $679.8K Ended 2022-12-31 | $2.68M Ended 2022-12-31 | $8.54M Ended 2022-12-31 |
| 4 years earlier | $81.0K Ended 2021-12-31 | n/a | n/a | $7.92M Ended 2021-12-31 |